Taken together, this is the first time that LC-ESI-MS/MS is used to detect the active compounds of HMMCR and integrate network pharmacology and in vitro experiments to explore the pharmacological mechanisms of HMMCR for non-small cell lung cancer, suggesting that HMMCR can efficiently inhibit NSCLC cellular proliferation and migration by regulating the PI3K/Akt signaling pathways. Here, AKT1 is linked to non-small cell lung carcinoma.